The Stockholm-3 (STHLM3) model included clinical variables (age, first-degree family history of prostate cancer, and a previous biopsy), blood biomarkers (total PSA, free PSA, ratio of free/total PSA, hK2, MIC1, and MSMB), genetic markers (a genetic score based on 254 single-nucleotide polymorphisms [SNPs] and an explicit variable for the HOXB13 SNP), and prostate examination (DRE, and prostate volume) [26]. This evidence concerns the gene KLK3 and Familial prostate cancer.